DOCSLIB.ORG

Statistical Review(S)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Statistical Review(S) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125509Orig1s000 STATISTICAL REVIEW(S) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Sciences Office of Biostatistics S TATISTICAL R EVIEW AND E VA LU ATI O N ANIMAL EFFICACY STUDIES NDA/BLA #: BLA 125509 Drug Name: Anthim®(obiltoxaximab) 16 mg/kg IV Indication(s): Treatment and Prophylaxis of Inhalational Anthrax due to Bacillus anthracis Applicant: Elusys Therapeutics, Inc. Date(s): Submission date: 3/20/2015. PDUFA due date: 3/18/2016 Review Priority: Standard Biometrics Division: Division of Biometrics IV Statistical Reviewer: Xianbin Li, PhD Concurring Reviewers: Karen Higgins, ScD Daphne Lin, PhD Medical Division: Division of Anti-Infective Products (DAIP) Clinical Team: Elizabeth O'Shaughnessy, MD, Medical Reviewer John Alexander, MD, Medical Team Leader Sumathi Nambiar, MD, Medical Director Project Manager: Jane Dean, RN MSN Keywords: Animal efficacy studies Reference ID: 3859664 Table of Contents 1 EXECUTIVE SUMMARY .................................................................................................. 11 2 INTRODUCTION ................................................................................................................ 12 2.1 OVERVIEW ........................................................................................................................ 12 2.2 DATA SOURCES ................................................................................................................ 13 3 STATISTICAL EVALUATION ......................................................................................... 13 3.1 DATA AND ANALYSIS QUALITY ........................................................................................ 13 3.2 EVALUATION OF EFFICACY ............................................................................................... 14 3.2.1 Introduction............................................................................................................... 14 3.2.2 IV Treatment Studies ................................................................................................. 14 3.2.3 Post-exposure Prophylaxis Studies ........................................................................... 27 3.2.4 Pre-exposure Prophylaxis Studies ............................................................................ 33 3.2.5 Re-challenge Study .................................................................................................... 35 3.3 EVALUATION OF SAFETY .................................................................................................. 36 4 FINDINGS IN SPEAL/SUBGROUP POPULATIONS .................................................... 38 4.1 GENDER, RACE, AGE, AND GEOGRAPHIC REGION ............................................................ 38 4.2 OTHER SPECIAL/SUBGROUP POPULATIONS ....................................................................... 38 5 SUMMARY AND CONCLUSIONS................................................................................... 39 5.1 STATISTICAL ISSUES ......................................................................................................... 39 5.2 COLLECTIVE EVIDENCE .................................................................................................... 39 5.2.1 Meta-analysis of monkey and rabbits monotherapy studies ........................................ 40 5.2.2 Meta-analysis of PEP studies in monkeys and rabbits ............................................. 40 5.2.3 Efficacy of Lonza ETI-204 ........................................................................................ 42 5.2.4 Summary of collective evidence ................................................................................ 43 5.3 CONCLUSIONS AND RECOMMENDATIONS ......................................................................... 45 5.4 LABELING RECOMMENDATIONS ....................................................................................... 45 6 APPENDICES ...................................................................................................................... 47 6.1 OVERVIEW ........................................................................................................................... 47 6.2 IV MONKEY TREATMENT STUDIES ................................................................................... 47 6.2.1 Summary of IV monkey treatment studies ................................................................. 47 6.2.2 AP201 ........................................................................................................................ 49 6.2.3 AP204 ........................................................................................................................ 58 6.2.4 AP203 ........................................................................................................................ 67 6.2.5 AP202 ........................................................................................................................ 77 6.2.6 NIAID1056 ................................................................................................................ 89 6.3 IV RABBIT TREATMENT STUDIES ..................................................................................... 97 6.3.1 Summary of IV rabbit treatment studies ................................................................... 97 6.3.2 AR021 ........................................................................................................................ 98 6.3.3 AR033 ...................................................................................................................... 105 6.3.4 NIAID1030 .............................................................................................................. 114 2 Reference ID: 3859664 6.3.5 NIAID1045 .............................................................................................................. 120 6.4 MONKEY POST-EXPOSURE PROPHYLAXIS STUDIES ........................................................ 127 6.4.1 Summary of monkey post-exposure prophylaxis studies ......................................... 127 6.4.2 AP107 ...................................................................................................................... 127 6.4.3 AP301 ...................................................................................................................... 132 6.4.4 AP307 ...................................................................................................................... 139 6.5 RABBIT POST-EXPOSURE PROPHYLAXIS STUDIES .......................................................... 147 6.5.1 Summary of rabbit post-exposure prophylaxis studies ........................................... 147 6.5.2 AR004 ...................................................................................................................... 147 6.5.2 AR007 ...................................................................................................................... 152 6.5.4 AR012 ...................................................................................................................... 156 6.5.5 AR034 – Phase I ...................................................................................................... 161 6.5.6 AR035 ...................................................................................................................... 172 6.5.7 AR037 ...................................................................................................................... 178 6.5.8 AR0315 .................................................................................................................... 185 6.6 MONKEY PRE-EXPOSURE PROPHYLAXIS STUDY ............................................................ 191 6.6.1 Summary of monkey pre-exposure prophylaxis study ............................................. 191 6.6.2 AP305 ...................................................................................................................... 191 6.7 RABBIT PRE-EXPOSURE PROPHYLAXIS STUDIES ............................................................ 198 6.7.1 Summary of rabbit pre-exposure prophylaxis studies ............................................ 198 6.7.2 AR001 ...................................................................................................................... 198 6.7.3 AR003 ...................................................................................................................... 203 6.8 RE-CHALLENGE STUDY (AR034 PHASE II) ..................................................................... 208 6.9 SUMMARY OF ALL REVIEWED MONOTHERAPY STUDIES .................................................. 209 3 Reference ID: 3859664 LIST OF TABLES Table 1: List of all treatment studies included in analysis ............................................................ 15 Table 2: Survival proportions in monotherapy treatment studies in cynomolgus monkeys (mITT population) .................................................................................................................................... 17 Table 3: Survival proportions in monotherapy treatment studies in cynomolgus monkeys (bacteremic population) ................................................................................................................ 19 Table 4. Pearson correlation coefficients between challenge dose, log10 bacteremia,
Load more

Recommended publications
  • These Highlights Do Not Include All the Information Needed to Use ANTHIM Safely and Effectively. See Full Prescribing Information for ANTHIM
    ANTHIM - obiltoxaximab solution Elusys Therapeutics, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANTHIM safely and effectively. See full prescribing information for ANTHIM. ANTHIM® (obiltoxaximab) injection, for intravenous use Initial U.S. Approval: 2016 WARNING: HYPERSENSITIVITY and ANAPHYLAXIS See full prescribing information for complete boxed warning. Hypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion (5.1) ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis (1.2, 2.4, 5.1) Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs (2.4, 5.1) INDICATIONS AND USAGE ANTHIM® is a monoclonal antibody directed against the protective antigen of Bacillus anthracis. It is indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. (1.1) Limitations of Use ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. (1.2, 5.1) The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. (1.2, 14) There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. (1.2, 8.4) ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. (1.2) ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis.
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • 125509Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125509Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS ACTION PACKAGE CHECKLIST APPLICATION INFORMATION1 If NDA, Efficacy Supplement Type: BLA #125509 BLA Supplement # (an action package is not required for SE8 or SE9 supplements) Proprietary Name: Anthim Applicant: Elusys Therapeutics, Inc. Established/Proper Name: obiltoxaximab Agent for Applicant (if applicable): Dosage Form: injection RPM: Jane A. Dean, RN, MSN Division: Division of Anti-Infective Products For ALL 505(b)(2) applications, two months prior to EVERY action: NDA Application Type: 505(b)(1) 505(b)(2) Efficacy Supplement: 505(b)(1) 505(b)(2) Review the information in the 505(b)(2) Assessment and submit the draft2 to CDER OND IO for clearance. BLA Application Type: 351(k) 351(a) Check Orange Book for newly listed patents and/or Efficacy Supplement: 351(k) 351(a) exclusivity (including pediatric exclusivity) No changes New patent/exclusivity (notify CDER OND IO) Date of check: Note: If pediatric exclusivity has been granted or the pediatric information in the labeling of the listed drug changed, determine whether pediatric information needs to be added to or deleted from the labeling of this drug. Actions Proposed action AP TA CR User Fee Goal Date is 3/20/16 Previous actions (specify type and date for each action taken) None If accelerated approval or approval based on efficacy studies in animals, were promotional materials received? Note: Promotional materials to be used within 120 days after approval must have been Received submitted (for exceptions, see http://www fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida nces/ucm069965.pdf).
    [Show full text]
  • Ride'n Drive on Government Waste
    NEWS Table 1 Anthrax countermeasures in development Company Product Stage of development BARDA contract Human Genome Sciences ABthrax (raxibacumab), a human mAb against anthrax protective Biologic license $151 million antigen (PA) application Emergent BioSolutions AV-7909, a combination of BioThrax (aluminum-adsorbed cell- Phase 2 $447.6 million free filtrates of unencapsulated Bacillus anthracis) and Coley Pharmaceutical’s VaxImmune (an unmethylated CpG-motif oligonucleotide that acts as an agonist of Toll-like receptor 9) Anthrax immune globulin (AIGIV), polyclonal antibodies raised Phase 1/2 $13 million against BioThrax Elusys Therapeutics Anthim (ETI-204), a humanized mAb against PA Phase 1 Up to $143 million PharmAthene SparVax, an injectable rPA absorbed on to hydrogel Phase 2 $3.9 million NIAID DynPort Vaccine Anthrax vaccine, an injectable rPA vaccine Phase 1 NA Medarex, a subsidiary of Valortim (MDX-1303), a fully human mAb against PA Phase 1 $1 million from the US Department Bristol-Myers Squibb of Defense (DoD) payable to partner PHarmAthene Advanced Life Sciences Restanza, a once-daily oral ketolide cethromycin that inhibits Preclinical $3.8 million from DoD B. anthracis protein synthesis Sources: Sagient Research, BiomedTracker and BARDA. NA, Not available. Even with government support, PharmAthene For the US government, anthrax treatment procurement contract with the Centers for and other companies working under biodefense remains a critical element in its biodefense Disease Control and Prevention of Atlanta, contracts face the stark reality of drug develop- strategies. Emergent Solutions currently Georgia, to manufacture and deliver 14.5 ment: 30% of all candidates that reach phase manufactures the only approved vaccine for million doses of BioThrax for the strategic 3 clinical trials within the eight-year BARDA anthrax based on protective antigen (PA).
    [Show full text]
  • PRESCRIBING INFORMATION • Pre-Medicate with Diphenhydramine
    ----------------------- DOSAGE AND ADMINISTRATION ----------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION • Pre-medicate with diphenhydramine. (2.1, 5.1) These highlights do not include all the information needed to use • Recommended Dosage of ANTHIM: ANTHIM safely and effectively. See full prescribing information for o Adult Patients: 16 mg/kg. (2.1) ANTHIM. o Pediatric Patients: (2.2) ➢ Greater than 40 kg: 16 mg/kg ANTHIM® (obiltoxaximab) injection, for intravenous use ➢ Greater than 15 kg to 40 kg: 24 mg/kg Initial U.S. Approval: 2016 ➢ Less than or equal to 15 kg: 32 mg/kg • Dilute the injection in 0.9% Sodium Chloride Injection, USP, before WARNING: HYPERSENSITIVITY and ANAPHYLAXIS administering as an intravenous (IV) infusion over 1 hour and 30 minutes. See full prescribing information for complete boxed warning. (2.3) • Administer ANTHIM in a monitored setting equipped to manage • Hypersensitivity reactions, including anaphylaxis, have been anaphylaxis. (2.4, 5.1) reported during ANTHIM infusion (5.1) • See Full Prescribing Information for instructions on preparation, dilution • ANTHIM should be administered in monitored settings by and administration of ANTHIM injection. (2.3, 2.4) personnel trained and equipped to manage anaphylaxis (1.2, 2.4, 5.1) --------------------- DOSAGE FORMS AND STRENGTHS --------------------- • Stop ANTHIM infusion immediately and treat appropriately if Injection: 600 mg/6 mL (100 mg/mL) solution in single-dose vial. (3) hypersensitivity or anaphylaxis occurs (2.4, 5.1) ------------------------------ CONTRAINDICATIONS ------------------------------ None (4) --------------------------- INDICATIONS AND USAGE ---------------------------- ANTHIM® is a monoclonal antibody directed against the protective antigen of ----------------------- WARNINGS AND PRECAUTIONS ----------------------- Bacillus anthracis. It is indicated in adult and pediatric patients for treatment Hypersensitivity reactions, including anaphylaxis (Boxed Warning, 1.2, 2.1, of inhalational anthrax due to B.
    [Show full text]
  • 125509Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125509Orig1s000 OTHER REVIEW(S) REGULATORY PROJECT MANAGER PHYSICIAN’S LABELING RULE (PLR) FORMAT REVIEW OF THE PRESCRIBING INFORMATION Complete for all new NDAs, BLAs, Efficacy Supplements, and PLR Conversion Labeling Supplements Application: BLA 125509 Application Type: New BLA Name of Drug/Dosage Form: Anthim (obiltoxaximab) Injection, for intravenous use Applicant: Elusys Therapeutics Receipt Date: March 20, 2015 Goal Date: March 18, 2016 1. Regulatory History and Applicant’s Main Proposals Elusys Therapeutics, Inc. submitted a new Biologics Licensing Application (BLA) under section 351(a) of the Public Health Service Act and 21CFR Part 601, Subpart H (Approval of a Biologic Product When Human Efficacy Studies are not Ethical or Feasible) Anthim (obiltoxaximab) with the following indications: treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and prophylaxis of inhaltional anthrax when alternative therapies are not available or are not appropriate. 2. Review of the Prescribing Information This review is based on the applicant’s submitted Word format of the prescribing information (PI). The applicant’s proposed PI was reviewed in accordance with the labeling format requirements listed in the “Selected Requirements for Prescribing Information (SRPI)” checklist (see Section 4 of this review). 3. Conclusions/Recommendations No SRPI format deficiencies were identified in the review of this PI. 4. Selected Requirements of Prescribing Information The Selected Requirement of Prescribing Information (SRPI) is a 41-item, drop-down checklist of important format elements of the prescribing information (PI) based on labeling regulations (21 CFR 201.56 and 201.57) and guidances.
    [Show full text]
  • Why Medicinal Chemists Need Molecular Biologists to Discover Biodefense Therapeutics
    Why medicinal chemists need molecular biologists to discover biodefense therapeutics Lecture Presented to the University of Hawaii, November 29 th , 2018 Why a medicinal chemist needs molecular biology to discover biodefense therapeutics Lecture includes two example cases: 1. Anthrax and 2. Botulinum Neurotoxin – History – Important Questions to consider for a Biodefense Therapeutic – Help From Molecular Biology: • Developing the Necessary Tools • Applying the Tools AMERITHRAX Timeline of events: https://www.cnn.com/2013/08/23/health/anthrax-fast-facts/index.html https://www.fbi.gov/history/famous-cases/amerithrax-or-anthrax-investigation Anthrax History “Plague of Boils” in the Old Testament may have been referring to Anthrax in 15 th century B.C. Egypt Use in biowarfare and bioterrorism • 1932 -1945, WWII. Anthrax (and other agents) used by Japanese against Chinese • 1951-1953, Korean War. Aerial delivery of Anthrax possibly used by U.S. against North Koreans (?) • 1979, Sverdlovsk, USSR. At least 68 deaths follow an accidental release of Anthrax spores from a biowarfare facility • 2001, AMERITHRAX. Unsolved (?) attacks with Anthrax spores sent through the U.S. Postal system kill 5 Bacillus anthracis • Anthrax Pathogen • Gram-Positive • Rod-shaped • Spores in Soil – World -wide – Hardy • Herbivore Disease – Cattle, Sheep, Horses, Mules, Goats – Incidental Human Infection Anthrax – forms of human disease • Inhalational: – Infection via inhaled spores – Long and variable dose-dependent incubation period (2-60 days) – Onset looks like flu: aches, cough, fever – Brief symptomatic improvement at day 3-4 is followed by rapid decline and death within 5-7 days (lungs lymph immunosuppression by toxins allows accelerated growth & dissemination) – Fatality 80 - 100% even with treatment (sepsis, shock) • Gastrointestinal: – From eating contaminated meat – Severe GI symptoms, bloody vomit – < 60% fatality with treatment • Cutaneous: – Skin lesions which ulcerate and turn black ( anthrakitis , Gr.
    [Show full text]
  • Monoclonal Antibody Therapies Against Anthrax
    Toxins 2011, 3, 1004-1019; doi:10.3390/toxins3081004 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Monoclonal Antibody Therapies against Anthrax Zhaochun Chen 1,*, Mahtab Moayeri 2 and Robert Purcell 1 1 Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; E-Mail: [email protected] 2 Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-301-594-2308; Fax: +1-301-402-0524. Received: 10 June 2011; in revised form: 6 August 2011 / Accepted: 10 August 2011 / Published: 15 August 2011 Abstract: Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors. Keywords: Bacillus anthracis; anti-PA mAbs; anti-LF mAbs; anti-EF mAbs; anti-capsule mAbs; post-exposure treatment of anthrax; a cocktail of mAbs 1.
    [Show full text]
  • Downloads/Drugs/Drugsafety/UCM231731
    Head et al. BMC Infectious Diseases (2016) 16:621 DOI 10.1186/s12879-016-1951-y REVIEW Open Access Alternative pre-approved and novel therapies for the treatment of anthrax Breanne M. Head1*, Ethan Rubinstein1ˆ and Adrienne F. A. Meyers1,2,3 Abstract Background: Bacillus anthracis, the causative agent of anthrax, is a spore forming and toxin producing rod-shaped bacterium that is classified as a category A bioterror agent. This pathogenic microbe can be transmitted to both animals and humans. Clinical presentation depends on the route of entry (direct contact, ingestion, injection or aerosolization) with symptoms ranging from isolated skin infections to more severe manifestations such as cardiac or pulmonary shock, meningitis, and death. To date, anthrax is treatable if antibiotics are administered promptly and continued for 60 days. However, if treatment is delayed or administered improperly, the patient’s chances of survival are decreased drastically. In addition, antibiotics are ineffective against the harmful anthrax toxins and spores. Therefore, alternative therapeutics are essential. In this review article, we explore and discuss advances that have been made in anthrax therapy with a primary focus on alternative pre-approved and novel antibiotics as well as anti-toxin therapies. Methods: A literature search was conducted using the University of Manitoba search engine. Using this search engine allowed access to a greater variety of journals/articles that would have otherwise been restricted for general use. In order to be considered for discussion for this review, all articles must have been published later than 2009. Results: The alternative pre-approved antibiotics demonstrated high efficacy against B.
    [Show full text]
  • Development of Therapeutic Antibodies for the Treatment Of
    Lu et al. Journal of Biomedical Science (2020) 27:1 https://doi.org/10.1186/s12929-019-0592-z REVIEW Open Access Development of therapeutic antibodies for the treatment of diseases Ruei-Min Lu1, Yu-Chyi Hwang1, I-Ju Liu1†, Chi-Chiu Lee1†, Han-Zen Tsai1†, Hsin-Jung Li1 and Han-Chung Wu1,2* Abstract It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. Thus, the market for therapeutic antibody drugs has experienced explosive growth as new drugs have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the US FDA, but there is still significant growth potential. This review summarizes the latest market trends and outlines the preeminent antibody engineering technologies used in the development of therapeutic antibody drugs, such as humanization of monoclonal antibodies, phage display, the human antibody mouse, single B cell antibody technology, and affinity maturation.
    [Show full text]
  • Drugs and Vaccines for the Common Defense: Refining FDA Regulation to Promote the Availability of Products to Counter Biological Attacks
    Journal of Contemporary Health Law & Policy (1985-2015) Volume 19 Issue 1 Article 5 2002 Drugs and Vaccines for the Common Defense: Refining FDA Regulation to Promote the Availability of Products to Counter Biological Attacks Gail H. Javitt Follow this and additional works at: https://scholarship.law.edu/jchlp Recommended Citation Gail H. Javitt, Drugs and Vaccines for the Common Defense: Refining FDA Regulation to Promote the Availability of Products to Counter Biological Attacks, 19 J. Contemp. Health L. & Pol'y 37 (2003). Available at: https://scholarship.law.edu/jchlp/vol19/iss1/5 This Article is brought to you for free and open access by CUA Law Scholarship Repository. It has been accepted for inclusion in Journal of Contemporary Health Law & Policy (1985-2015) by an authorized editor of CUA Law Scholarship Repository. For more information, please contact [email protected]. DRUGS AND VACCINES FOR THE COMMON DEFENSE: REFINING FDA REGULATION TO PROMOTE THE AVAILABILITY OF PRODUCTS TO COUNTER BIOLOGICAL ATTACKS Gail H. Javitt* "Biologicalterrorism is more likely than ever before and far more greatly to be feared than explosives or chemicals." - D.A. Henderson' I. INTRODUCTION The 1991 Gulf War heightened military concerns about biological warfare. As a result of intelligence gained regarding Iraq's biological weapons stockpile and research program, as well as information obtained about the former Soviet Union's clandestine bioweapons program, the Department of Defense (DOD) began to intensify its focus on biowarfare defense. DOD was particularly concerned about protecting the U.S. military from exposure to biological agents, and in 1997 former Secretary of Defense Cohen ordered the-vaccination of all troops against anthrax.
    [Show full text]
  • Full Report (PDF)
    Next-Generation Monoclonal Antibodies: Challenges and Opportunities Center for Biosecurity of UPMC Final Report – February 2013 Center for Biosecurity Project Team Gigi Kwik Gronvall, PhD Anita Cicero, JD Senior Associate Chief Operating Officer and Deputy Director Kunal J. Rambhia, MS Tom Inglesby, MD Managing Senior Analyst Chief Executive Officer and Director Amesh Adalja, MD Robert Kadlec, MD Senior Associate RPK Consulting, LLC This project was supported by DTRA Chem Bio Directorate, and in collaboration with TASC, Inc, under contract #HDTRA1-11-D-0004. CONTENTS SECTION Page Summary of Findings: Next-Generation Monoclonal Antibodies .....................................................1 Purpose, Methods, and Analysis ..........................................................................................................4 Findings .................................................................................................................................................5 1. As a technology platform, monoclonal antibodies have value for DOD as a defense against bioweapons and emerging infectious diseases. ....................................5 2. Although commercial development of mAb technologies is mature, mAbs are not commonly used to prevent or treat infectious diseases. ...................... 19 3. mAbs are poised to play a critical role in infectious disease management. .............. 24 4. High cost per dose is a hallmark of mAbs, but costs are dropping. ............................ 26 5. Monoclonal antibody products have
    [Show full text]